Prelude Capital Management, LLC Fate Therapeutics Inc Transaction History

Prelude Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $345,958 - $558,776	-5,837 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $114,325 - $157,284	1,700 Added 41.09%	5,837 $507,000
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $528,841 - $1.4 Million	-13,884 Reduced 77.04%	4,137 $376,000
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $78,244 - $104,206	2,573 Added 16.66%	18,021 $720,000
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $312,204 - $544,233	15,448 New	15,448 $530,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $235M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.